Eterna Therapeutics Inc.

Brooklyn ImmunoTherapeutics, Inc. is a clinical stage biopharmaceutical company specializing in developing innovative therapies for cancer treatment. Its primary focus is on the advancement of IRX-2, currently in a Phase 2b clinical trial for squamous cell cancer of the head and neck. Additionally, the company is leveraging gene-editing and cell therapy technology to develop treatments for oncology, blood disorders, and monogenic diseases.

Products

• IRX-2 therapy for squamous cell cancer

• Gene-editing and cell therapy treatments for oncology, blood disorders, and monogenic diseases